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Abstract
Background: Controlled clinical trials of health care interventions are either explanatory or
pragmatic. Explanatory trials test whether an intervention is efficacious; that is, whether it can have
a beneficial effect in an ideal situation. Pragmatic trials measure effectiveness; they measure the
degree of beneficial effect in real clinical practice. In pragmatic trials, a balance between external
validity (generalizability of the results) and internal validity (reliability or accuracy of the results)
needs to be achieved. The explanatory trial seeks to maximize the internal validity by assuring
rigorous control of all variables other than the intervention. The pragmatic trial seeks to maximize
external validity to ensure that the results can be generalized. However the danger of pragmatic
trials is that internal validity may be overly compromised in the effort to ensure generalizability.
We are conducting two pragmatic randomized controlled trials on interventions in the
management of hypertension in primary care. We describe the design of the trials and the steps
taken to deal with the competing demands of external and internal validity.
Discussion:  External validity is maximized by having few exclusion criteria and by allowing
flexibility in the interpretation of the intervention and in management decisions. Internal validity is
maximized by decreasing contamination bias through cluster randomization, and decreasing
observer and assessment bias, in these non-blinded trials, through baseline data collection prior to
randomization, automating the outcomes assessment with 24 hour ambulatory blood pressure
monitors, and blinding the data analysis.
Summary: Clinical trials conducted in community practices present investigators with difficult
methodological choices related to maintaining a balance between internal validity (reliability of the
results) and external validity (generalizability). The attempt to achieve methodological purity can
result in clinically meaningless results, while attempting to achieve full generalizability can result in
invalid and unreliable results. Achieving a creative tension between the two is crucial.
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Background
Controlled clinical trials of health care interventions are
either explanatory or pragmatic. [1-8] Explanatory trials
test whether an intervention is efficacious; that is, whether
it can have a beneficial effect in an ideal situation. These
trials are often conducted in large tertiary care, referral-
based, health centres on a homogenous group of patients,
who have demonstrated compliance, who are likely to
remain in the study, and who often have no medical con-
dition other than the one under treatment.
Pragmatic trials measure effectiveness; they measure the
degree of beneficial effect in real clinical practice. Prag-
matic trials are conducted on patients who represent the
full spectrum of the population to which the treatment
might be applied. These patients may demonstrate varia-
ble compliance, have a number of co-morbid conditions,
and use other medications. If an intervention is shown to
have a significant beneficial effect in a pragmatic trial then
it has been shown not only that it can work, but also does
work in real life.
The explanatory clinical trial remains the standard for
assessing drug efficacy and is required for drug licensure in
most countries. Testing the efficacy of medications and
other interventions in explanatory controlled clinical tri-
als is critical to the progress of medicine. It is necessary,
but it is not always sufficient. The overall effectiveness of
a treatment is best assessed by carefully designed and well
conducted pragmatic randomized trials. Pragmatic trials
inform practitioners and health care planners on the most
clinically effective and cost effective treatments. However
there is a critical issue that needs to be considered in prag-
matic trials; that is the balance between external validity
(generalizability of the results) and internal validity (reli-
ability or accuracy of the results). Whereas the explanatory
trial seeks to maximize the internal validity by assuring
rigorous control of all variables other than the interven-
tion, the pragmatic trial seeks to maximize external valid-
ity to ensure that the results can be generalized. However
the danger of pragmatic trials is that internal validity may
be overly compromised in the effort to ensure
generalizability.
We are conducting two pragmatic randomized controlled
trials on interventions in the management of hyperten-
sion in primary care. We will use these two studies as
examples to help the discussion around achieving a bal-
ance between internal and external validity in pragmatic
trials conducted in a practice setting.
Trial 1: a randomized controlled trial of the effects of 
home blood pressure monitoring (HBPM) on blood 
pressure control
This is a randomized controlled clinical trial of HBPM
(intervention group) compared to usual care (control
group). Randomization is by physician. The intervention
involves once a week measurements of blood pressure at
home, and the reporting of these measurements to the
family doctor at each office visit. The primary outcome is
blood pressure control measured by 24-hour ambulatory
blood pressure monitoring (ABPM) at entry, and after 6
and 12 months. Secondary outcomes include the number
of office visits for hypertension, change in lifestyle behav-
iors by patient, lifestyle counseling by the physician, qual-
ity of life of the patient, medication compliance, and
intensity of treatment. (Figure 1)
Trial 2: an intensive scheduled management (ISM) strategy 
for increasing blood pressure control in patients in primary 
care
This is a randomized controlled trial, in the primary care
setting, comparing intensive scheduled management of
hypertension (aggressive achievement of target blood
pressure over 16 weeks) with usual management of hyper-
tension. Randomization is by physician. The primary out-
come is blood pressure control on 24-hour ABPM; it is
measured at 16 weeks to determine the short-term effect
of the intensive approach to therapy and again at 1 year to
determine if the blood pressure control is maintained.
Secondary outcomes include patient quality of life, physi-
cian compliance with the intensive protocol, patient com-
pliance with medication, and adverse effects. (Figure 2)
Discussion
Inclusion/exclusion criteria
A hallmark of pragmatic trials is that the participants
reflect the population for which the treatment is intended.
Exclusion criteria are kept to a minimum. In both our
studies the patient population (inclusion criteria) consists
of "adults, age 18 years and older, who have been diag-
nosed with essential hypertension and who have not
reached their target blood pressure level." Exclusion crite-
ria common to both studies are patients with "a diagnosis
of secondary hypertension; pregnancy; hypertension
management primarily by a consultant; inability to pro-
vide informed consent". Particular to the HBPM study is
the exclusion criteria "a physical or mental disability that
precludes use of a home blood pressure monitor".
All adults with uncontrolled essential hypertension con-
stitute the target population. Patients are not excluded for
co-morbid conditions or if medication is already being
used. We accept the family physician's diagnosis of essen-
tial hypertension without doing any confirmatory tests,
because this is what happens in practice, and becauseBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/28
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essential hypertension is, by far, the most likely diagnosis
in primary care. Children and pregnant women are
excluded because they are not part of the population for
which the interventions are intended. And finally, since
this is a trial of the primary care management of hyperten-
sion, patients whose blood pressure is a managed by
hypertension specialists are excluded.
The interventions
For the HBPM study the intervention consists of the pro-
vision of a home blood pressure monitor to each patient
in the intervention group, patient instruction on its
proper use, a recording frequency of at least once a week,
and the reporting of the results of the HBPM to the physi-
cian at each office visit. The patient may use the HBPM
more often than weekly if they wish; the frequency of vis-
its to the physician is determined by the physician and the
patient; and the physicians may choose to use the HBPM
information presented to them by the patients in the
manner they feel most appropriate. We postulate several
mechanisms by which the intervention may improve
blood pressure: bringing in the HBPM measurements to
the physician may lead to enhanced discussion between
the physician and patient about the value of controlling
high blood pressure and the lifestyle changes that can lead
to improved blood pressure control and health outcomes;
the patients' knowledge of their blood pressure may influ-
ence them to adhere to their medication regime and make
appropriate life style changes; it may also influence the
patient and the physician's management of uncontrolled
hypertension, by increasing the intensity of treatment.
For the ISM study, the intervention includes both the
eight visits (every two weeks for 16 weeks) to see their
family doctor and the adjustment of medications at each
visit to achieve target blood pressure levels. This study is
designed to test the premise that guidelines, to be effective
in primary care, need to be operationalized for the practi-
tioner. To this end we have devised a protocol where med-
ications are initiated at the recommended starting dose
Schematic for the HBPM study Figure 1
Schematic for the HBPM study
Intervention Group
Patients receive Home Blood Pressure Monitors
Measure their BP weekly
Report results to physicians
Control Group
Usual Care
Primary Outcomes
Blood pressure Control Based on 24 hour ABPM
Secondary Outcomes
Behavioural Outcomes Based on Patient Interview
and Chart Abstraction
Data Analysis
Outcomes Measured at 6 and 12 months
Cluster Randomization of Patients by Physician
Determination of Patient Eligibility and Collection of Baseline Data
Physician/Patient RecruitmentBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/28
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and increased by one recommended increment before
adding the next drug. The goal is to increase the
medications over the 16-week period such that, if neces-
sary to reach the target blood pressure level, a patient is on
a medium dose of three different antihypertensive agents
(medium dose is being defined as one recommended
increment above the recommended starting dose).
The pragmatic nature of this trial allows the choice of
medications to be decided by the physician, but it is rec-
ommended that guideline choices be followed. As well, in
keeping with real life and generalizability, the physician,
when making decisions about increasing a patient's drug
regime intensity, will be able to take into account medica-
tion compliance, side effects, and life events that may
cause transient elevations of the patient's blood pressure.
(Figure 3)
Recruitment and randomization
The intervention in both trials is dependent on physician
behavior. There is a risk that if an individual physician
had patients in both the intervention and control groups,
the modification of behaviour caused by the intervention
would affect the management of patients in the control
group. To prevent this we use cluster randomization; the
physician is randomized to the intervention or control
group rather than the individual patients. All patients of a
given physician are then enrolled into the group to which
their physician has been assigned. Because we want the
research assistant who collects the enrollment data to be
blinded to the patient group allocation, we have to enroll
all patients of a given physician before randomizing that
physician. This means we cannot enroll a physician's
patients in an ongoing manner as they become available
but have to identify them all at one time, seek consent,
and do all the enrollment work before assigning them to
a group.
Blinding
As is often true for pragmatic trials, it is not possible to
blind either the physicians or the patients in either of the
studies. However attempts have to be made to 'blind' as
much of the process as is possible. The main outcomes are
based on 24-hour ambulatory blood pressure recordings
that provide an independent measurement of blood pres-
sure; the biostatistician analyzing the data will be blinded
to the group assignment; and enrollment data will be
Schematic for the ISM study Figure 2
Schematic for the ISM study
Intervention Group
Intensive Scheduled Management
Eight weekly appointments with scheduled adjustments in medication
 at each visit until target blood pressures achieved
Control Group
Usual Care
Primary Outcomes
Blood pressure Control Based on 24 hour ABPM
Secondary Outcomes
Quality of Life
Compliance with Medications
Adverse Effects
Data Analysis
Outcomes Measured at 8 weeks and  6 and 12 months
Cluster Randomization of Patients by Physician
Determination of Patient Eligibility and Collection of Baseline Data
Physician/Patient Recruitment
Intervention Group
Intensive Scheduled Management
One appointment every two weeks for 16 weeks. Protocol based 
adjustments in medications until target blood pressures 
achieved.
Outcomes Measured at 16 weeks and 12 monthsBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/28
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collected by the research assistant prior to the group
assignment.
Contamination
Our main strategy for reducing contamination in both
studies is the use of cluster randomization so that all
enrolled patients under a given physician's care are either
in the intervention group or the control group. Contami-
nation is still possible, especially for the HBPM study. We
hope to reduce it by asking patients in the control group
not to use a home blood pressure monitor and ask control
group physicians to refrain from recommending HBPM to
their patients during the 12 months of the study. At the
time of the 24-hour ABPM, patients will be asked to com-
plete a questionnaire regarding blood pressure measure-
ment outside the physician's office. Regarding
contamination in the ISM study, it is possible that control
group physicians will take it upon themselves to start an
intensive scheduled approach to management of blood
pressure, but we believe this is unlikely.
Compliance with the intervention
To a great extent, compliance with the intervention is one
of the most important outcomes of pragmatic trials.
Unlike explanatory trials where compliance with the
intervention must be ensured in order to know that the
intervention can work, in pragmatic trials compliance
with the intervention is measured as an outcome. If phy-
sicians and/or patients do not complied with the interven-
tion, then it doesn't matter that it can work in the ideal
world, because in the real world it doesn't. Of course, rea-
sonable attempts are made to encourage compliance with
the intervention but these must not go beyond what could
be expected in the normal course of practice. We are
assessing compliance with home blood pressure monitor-
ing by having patients record their activity in a diary and
Sample page from the visit form of the ISM study Figure 3
Sample page from the visit form of the ISM study
Pragmatic controlled clinical trials
1
DRUG#1: 
DRUG#2:
DRUG#3: 
1. BP #1: ______________________  BP #2: ________________________  BP target achieved (2
nd reading)?  YES  NO
2. Do you have reason to believe today’s BP is not representative of patient’s usual BP?  YES  NO
(e.g. acute stressful situation, life crisis, home BP measurement, etc.)
3. Does the patient state that they have taken their antihypertensive medications 80% of the time?  YES  NO
4. Is the patient having significant or unusual side effects from the medication?  YES  NO
ACTION:
Both diastolic and systolic BP targets are reached?
  NO  YES  I will recheck the BP in two weeks.
If NO (one or both targets are not reached), did you increase medication?
 YES              NO
ANTIHYPERTENSIVE MEDICATION REGIME AT END OF THIS VISIT
VISIT #1
Please see this patient again in two weeks
IF MEDICATION NOT INCREASED:
  Patient not compliant with current medications. Compliance discussed 
and patient encouraged to take medications as prescribed.
 BP not representative due to stress etc. Will recheck BP in 2 weeks 
before changing medication.
 Medication side effects.
 Medication discontinued; new medication started.
 Medication discontinued; new medication NOT started.
 Medication decreased; new medication started.
 Medication decreased; new medication NOT started.
 Medication not changed. Will wait and see if side effects settle.
IF MEDICATION INCREASED:
 Increased an existing antihypertensive agent by one
recommended increment. (see table of drug dosages)
 Started a new antihypertensive agent at the recommended 
initial dose.BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/28
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bring it to their physician. We are assessing compliance
with the intensive scheduled management of hyperten-
sion intervention by having the physician record whether
they followed the protocol and if not their reasons for it.
(figure 3)
Follow-up and outcomes measurement
In both studies the patients are followed for one year.
Data is collected at baseline and then again at 6 and 12
months for the HBPM study and at 16 weeks and 12
months for the ISM study. There are three methods of out-
come assessment: 24 hr ambulatory blood pressure mon-
itoring, patient interview, and chart abstraction. For both
studies the mean daytime systolic and diastolic blood
pressures from the 24 hour ABPM will be used as the pri-
mary outcome. Patient interview/questionnaire comple-
tion will be used to collect information on quality of life
(SF36), lifestyle risk factors (using the Short Lifestyle Indi-
cator Questionnaire or SLIQ which we have developed for
the HBPM study), and patient reporting of compliance.
For the HBPM study only, the intensity of treatment, the
degree to which lifestyle issues were addressed by the phy-
sician, and the frequency of visits for hypertension will be
assessed chart abstraction
The struggle between external and internal validity
The need to balance external validity and internal validity
is ever-present in pragmatic randomized controlled trials.
These two trials provide examples of the issues that are
often encountered and how they can be addressed. Exter-
nal validity, or generalizability, was addressed in both
studies by having very few exclusion criteria. Hyperten-
sion patients are a heterogeneous group, and patients with
multiple and varying co-morbidities and medication
usage were all included. One of the strengths of a rand-
omized trial is that the diversity of the study population is
distributed between the two groups and thus helps main-
tain internal validity. In addition to minimizing the exclu-
sion criteria, we enhanced external validity of the HBPM
study by allowing the patients to use the home blood
pressure monitor as often as they wanted with the require-
ment that they use it at least once a week. This ensures that
the minimum intervention occurs and allows for the prag-
matic fact that patients will use the machine at variable
frequencies; it reflects what happens in practice when a
patient obtains a home BP monitoring device. In a similar
vein, in the HBPM study physicians were free to manage
the hypertension and to use the results of the home blood
pressure monitoring as they saw fit. In the ISM study,
while the management regime is much more regulated,
the physician has the freedom to choose a course of action
different from the protocol if it is felt to be in the best
interest of the patient. This is fundamentally pragmatic
and has to be permitted if the results are to be accepted as
generalizable. Again, conservation of internal validity is
achieved through the random distribution of the different
management approaches between the intervention and
control groups. While this assumption of 'equal distribu-
tion of differences by randomization' is not absolute, it
remains the best way to achieve internal validity in a trial
that maximizes external validity. It underscores the
importance of randomization in pragmatic trials.
Internal validityis the extent to which differences between
the intervention and control groups can be confidently
attributed to the intervention and not due to some alter-
nate explanation. To achieve this, confounding factors
and bias must be reduced to a minimum. In a pragmatic
trial this is more difficult because of the competing
demand of external validity. We worked to increase the
internal validity of the study using multiple strategies.
Cluster randomization was used to decrease the likeli-
hood of contamination bias by ensuring that physicians
did not apply strategies used in the intervention patients
to control patients. To further prevent contamination bias
in the HBPM study we are enlisting the cooperation of the
patients in the control group by asking them not to begin
using home blood pressure monitors during the study
period. Unable to blind patients or physicians, we are
using the techniques of baseline data collection before
randomization, automation of outcome assessment, and
blinding of the data analysis to decrease observer and
assessment bias.
It is possible that our efforts to overcome the effects of
pragmatism on internal validity will be only partially suc-
cessful. Patients in the control group of the HBPM study
may start using home blood pressure monitoring despite
asking them not to; or they may start checking there blood
pressure in pharmacies. We can deal with this only by
measuring it (asking them) and attempting to control for
its effect in the analysis. We also do not know ahead of
time whether control group physicians in the ISM study
will increase the intensity of treatment for their patients
because they have volunteered to be ina study and they
have heard in general terms about the intervention. While
we request that they do not change their usual practice
during the study, we will measure changes and control for
it in the analysis. The possibility that randomization will
fail to distribute factors equally between groups and the
occurrence of contamination due to lack of true blinding
must be considered when planning the sample size and
analysis of a pragmatic trial. Hence a plan for analysis
must be in place where there is sufficient sample size to
allow for regression analysis to determine the independ-
ent effects of the intervention taking potential confound-
ers into account.
Table 1 (see Additional file 1) provides a summary of the
differences between explanatory and pragmatic trials. To aBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/28
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great extent the conduct of pragmatic trials is a recent
phenomenon. While one of the earlier descriptions of
pragmatic versus explanatory trials was by Schwartz in
1967 [7] and again by MacRae in 1989 [8], most of the
published editorials considering pragmatic trials as a
methodology have been since 1998 [1-6]. These commen-
taries do not differ substantially from this article in tone
and concept. However we have extended the information
in the literature by addressing how the various issues can
be dealt with when designing a pragmatic trial and by
using two examples to shed further light on the process.
The recent increase in published pragmatic trials indicates
the relevance of this methodology, particularly in primary
care. A Medline search using pragmatic as a title word and
limited to randomized controlled trials yielded 34 articles
reporting on pragmatic clinical trials. All 34 were pub-
lished since 1995 and 26 of them were published since
2000. Of the 34 pragmatic trials 13 (38%) were conducted
in primary care practice settings. Investigators using this
method understand its strengths and weaknesses.
Summary
Clinical trials conducted in community practices present
investigators with difficult methodological choices related
to maintaining a balance between internal validity (relia-
bility of the results) and external validity
(generalizability).
To maintain generalizability i) exclusion criteria must be
kept to a minimum, and ii) physicians and patients (who
actually deliver the intervention in the course of regular
physician patient encounters) must be given a large degree
of freedom in making choices about the delivery of the
intervention in order to keep it pragmatic and to ensure
that patients are not harmed.
To maintain internal validity i) randomization is critical,
ii) cluster randomization is often needed to deal with con-
tamination issues, and iii) data collection and data
analysis must be blinded whenever possible since stand-
ard double-blind strategies are often not possible.
Compliance is not something you necessarily struggle to
maintain but rather something you measure as an out-
come. Lack of compliance in the 'real world' frequently
renders an efficacious intervention ineffective.
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